NDA 4056, held by Bristol Myers Squibb. Diethylstilbestrol.
As of Nov 14, 2026, NDA 4056 (Stilbestrol, Stilbetin), held by Bristol Myers Squibb, was not approved, with 0 approved supplements and 0 published complete response letters.
| Stilbestrol0.1MG · suppository;vaginal | Diethylstilbestrol | Discontinued |
| Stilbestrol0.5MG · suppository;vaginal | Diethylstilbestrol | Discontinued |
| Stilbestrol0.2MG/ML · injectable;injection | Diethylstilbestrol | Discontinued |
| Stilbestrol0.5MG/ML · injectable;injection | Diethylstilbestrol | Discontinued |
| Stilbestrol1MG/ML · injectable;injection | Diethylstilbestrol | Discontinued |
| Stilbestrol5MG/ML · injectable;injection | Diethylstilbestrol | Discontinued |
| Stilbetin0.1MG · tablet;oral | Diethylstilbestrol | Discontinued |
| Stilbetin0.5MG · tablet;oral | Diethylstilbestrol | Discontinued |
| Stilbetin1MG · tablet;oral | Diethylstilbestrol | Discontinued |
| Stilbetin5MG · tablet;oral | Diethylstilbestrol | Discontinued |
| Stilbetin0.1MG · tablet, delayed release;oral | Diethylstilbestrol | Discontinued |
| Stilbetin0.5MG · tablet, delayed release;oral | Diethylstilbestrol | Discontinued |
| Stilbetin1MG · tablet, delayed release;oral | Diethylstilbestrol | Discontinued |
| Stilbetin5MG · tablet, delayed release;oral | Diethylstilbestrol | Discontinued |
| Stilbetin0.25MG · tablet;oral | Diethylstilbestrol | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
